Summary
This study, conducted by American researchers, determined vitamin B12 levels in patients with early Parkinson’s disease and their association with the progression of the disease. During the study, vitamin B12 and vitamin B12 determinants like homocysteine (a risk factor for several disorders) were measured in blood collected from participants with early, untreated Parkinson’s disease. Additionally, disease progression was measured by a specific disease rating scale (UPDRS) and a questionnaire indicating cognitive dysfunction (e.g., amnesia or dementia). Low vitamin B12 levels were common in patients with early Parkinson’s disease and predicted greater worsening of mobility, whereas elevated homocysteine predicted greater cognitive decline. The scientists suggest that low vitamin B12 and high homocysteine levels may be improved through vitamin supplementation. More details can be found in the study.
References
Christine et al.